Page 3 - Aad Shrine News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Aad shrine. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Aad Shrine Today - Breaking & Trending Today

Building a Psoriasis Knockout Regimen Around Risankizumab, with Andrew Blauvelt, MD, MBA

Blauvelt discusses the future research of higher-dose risankizumab for patients with psoriasis and why it may be "disruptive in the treatment space." ....

United States , San Diego , Andrew Blauvelt , American Academy Of Dermatology , Oregon Medical Research Center , American Academy , Aad 2024 , Sandy Blauvelt ,

Iltefat Hamzavi, MD: Long-Term Implications of New Data on Upadacitinib for Nonsegmental Vitiligo

In this segment of his AAD interview, Hamzavi discussed more about his team’s findings on upadacitinib as well as their implications and future in terms of research. ....

United States , Iltefat Hamzavi , American Academy Of Dermatology , Henry Ford Health System Department , Global Vitiligo Foundation , Henry Ford Health System ,

Jonathan Silverberg, MD, PhD: New Phase 3 Findings on Nemolizumab for Atopic Dermatitis

This interview at AAD featured a discussion with Silverberg on nemolizumab’s efficacy and safety at Week 48 among patients with moderate-to-severe atopic dermatitis.
....

United States , San Diego , Jonathan Silverberg , George Washington University School Of Medicine , European Academy Of Dermatology , American Academy Of Dermatology , Health Sciences , Annual Meeting , George Washington University School , European Academy , Investigator Global Assessment , Atopic Dermatitis , Phase 3 ,

Discussing New Phase 2 Findings on Lutikizumab for Hidradenitis Suppurativa with Alexa Kimball, MD, MPH

Kimball discusses her team’s new late-breaking data regarding the safety and effectiveness of lutikizumab in treating the symptoms of moderate-to-severe HS in adult non-responders to anti-TNF therapy.
....

United States , Alexa Kimball , Harvard Medical School , American Academy Of Dermatology , Annual Meeting , Hidradenitis Suppurativa Clinical Response , Massachusetts General Hospital , Numeric Rating Scale , Global Assessment , Hidradenitis Suppurativa , Anti Tnf , Phase 2 , Late Breaking ,

Ruxolitinib Cream Is Tolerable and Effective in Cutaneous GVHD

A cream formulation of ruxolitinib was deemed safe and effective compared with placebo in patients with cutaneous graft-versus-host disease. ....

Galina Markova , Cellular Therapy Meetings , Inpatient Consultative Dermatology , Dermatology Service , Memorial Sloan Kettering Cancer Center , Global Assessment , Clinical Condition , Composite Assessment , Index Lesion Disease Severity , Dermtech Smart , Cream Formulation Of Ruxolitinib , Patients With Cutaneous Graft Versus Host Disease ,